New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
06:31 EDTWMGIWright Medical upgraded to Strong Buy from Buy at Needham
Needham upgraded Wright Medical to Strong Buy citing the strong Q1 report. Price target is $40.
News For WMGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
12:57 EDTWMGIOn The Fly: Midday Wrap
Subscribe for More Information
10:12 EDTWMGIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:12 EDTWMGIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Buffalo Wild Wings (BWLD) upgraded to Outperform at RW Baird... CPFL Energia (CPL) upgraded to Buy from Neutral at UBS... Core Laboratories (CLB) upgraded to Overweight from Equal Weight at Morgan Stanley... Dril-Quip (DRQ) upgraded at Morgan Stanley... DryShips (DRYS) upgraded to Outperform from Underperform at Imperial Capital... FireEye (FEYE) upgraded to Positive from Mixed at OTR Global... GOL Linhas (GOL) upgraded to Outperform from Market Perform at Raymond James... Madison Square Garden (MSG) upgraded to Buy from Hold at ISI Group... Nobel Biocare (NBHGY) upgraded to Neutral from Underweight at JPMorgan... STMicroelectronics (STM) upgraded to Neutral from Sell at Citigroup... Trinity Industries (TRN) upgraded to Positive from Neutral at Susquehanna... Twitter (TWTR) upgraded to Hold from Sell at Pivotal Research... Wal-Mart de Mexico (WMMVY) upgraded to Overweight from Equal Weight at Barclays... Wright Medical (WMGI) upgraded at RBC Capital... XL Group (XL) upgraded to Hold from Sell at Deutsche Bank.
09:20 EDTWMGIOn The Fly: Pre-market Movers
Subscribe for More Information
08:57 EDTWMGIWright Medical upgraded at RBC Capital
Subscribe for More Information
08:56 EDTWMGIWright Medical downgraded to Neutral from Buy at Summer Street
Subscribe for More Information
08:45 EDTWMGIWright Medical, Tornier merger positive, says BMO Capital
Subscribe for More Information
08:33 EDTWMGIWright Medical price target raised to $45 from $40 at Brean Capital
Subscribe for More Information
07:29 EDTWMGITornier downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
07:13 EDTWMGIWright Medical removed from Focus List at JPMorgan
Subscribe for More Information
06:38 EDTWMGIWright Medical downgraded to Buy from Strong Buy at Needham
Subscribe for More Information
06:24 EDTWMGIWright Medical upgraded to Outperform from Sector Perform at RBC Capital
05:32 EDTWMGITornier downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded Tornier (TRNX) to Market Perform citing the merger deal with Wright Medical (WMGI). Wells sees a low likelihood of another suitor emerging.
October 27, 2014
18:26 EDTWMGIOn The Fly: After Hours Movers
Subscribe for More Information
16:29 EDTWMGIWright Medical sees Tornier deal accretive to adjusted EBITDA in second year
Subscribe for More Information
16:29 EDTWMGIWright Medical to acquire Tornier in all-stock deal, own 52% of combined company
Subscribe for More Information
16:25 EDTWMGIWright Medical announces receipt of FDA approvable letter for Augment bone graft
Wright Medical Group announced that its BioMimetic subsidiary has received an Approvable Letter from the FDA for its Premarket Approval Application for Augment Bone Graft. The approvable letter indicates that FDA determined Augment Bone Graft to be safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications and is approvable subject to customary preapproval facilities inspections. Robert Palmisano, president and CEO of Wright Medical, stated, “Today’s positive news on the approvability of Augment Bone Graft is a major milestone that paves the way for commercialization in the U.S. and further underscores our strength in Biologics. Augment will provide clear benefits to patients and physicians and is expected to be a significant catalyst and meaningful new future growth driver for our business. We will work swiftly to address the inspection requirements set forth in the approvable letter and expect our U.S. foot and ankle commercial team to be ready to launch immediately upon final approval.” The company will work with the FDA to coordinate any preapproval inspections. Assuming satisfactory completion of this activity and receipt of a final approval order from the FDA, commercial sale and distribution of Augment Bone Graft can begin in the U.S.
16:19 EDTWMGIWright Medical, Tornier agree to merge in $3.3B transaction
Subscribe for More Information
October 17, 2014
07:31 EDTWMGIWright Medical risk/reward positive into FDA decision, says JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use